"The Report COPD
Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by
Rising Prevalence, Growing Awareness and Expected Launch of Novel
Therapies provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
The
new market report analyzes the chronic obstructive pulmonary disease
(COPD) therapeutics market in Asia Pacific and discusses recently
launched COPD products and approved novel drugs that will complement
current market leaders and offer better therapeutic alternatives. The
report predicts the growth of the COPD market in five Asia Pacific
countries namely, India, China, Australia, South Korea, and Japan.
The
report – titled ‘COPD
Therapeutics in Asia-Pacific Markets
To 2022 - Growth Driven by Rising Prevalence, Growing Awareness and
Expected Launch of Novel Therapies’ – estimates that the Asia
Pacific COPD therapeutics market will grow at a CAGR of 10.2%, from
its initial value of US$3.7 billion in 2015 to US$7.3 billion in
2022. The report further mentions various drivers and barriers that
will influence the market over the forecast period.
Chronic
obstructive pulmonary disease (COPD) affects not only the geriatric
population, but a large section of the society due to excessive
smoking. Many are known to suffer from this disease for years, and
die of it or its complications, thereby increasing the burden
economically and socially. The COPD burden is expected to grow in the
coming years, industry experts predict.
Due
to an increase in the number of smokers around the world, the disease
will continue to be a major health concern for a long period. The
demand for COPD therapeutics is set to prosper with the given number
of people suffering from COPD. Wide range of treatments are available
in the market such as bronchodilator monotherapies, bronchodilator
and ICS combinations, bronchodilator combinations, and PDE-4
inhibitors. The launch of new products and the approval of novel
drugs are fueling market growth. The market is set to go through a
transitional phase, with more focus towards triple and targeted
combination drug treatments.
Get Sample Copy Of This Report
@ http://www.marketresearchreports.biz/sample/sample/938607
Bronchodilators
and ICS lead the COPD market; however, they still lack safety and
efficiency. The treatments currently available are managing the
occurrence and severity of the symptoms, but none of them have shown
any long-term disease progression. The focus is now on drugs under
development, so as to meet the unmet needs of the COPD therapeutics
market.
Japan
is a key contributor towards the growth of the Asia Pacific COPD
therapeutics market. The growth of the market in this country can be
attributed to the emergence of novel therapies. The rate of
technological and medical developments and government initiatives to
improve lifestyle are a few factors driving the market.
View Press Release @
http://www.marketresearchreports.biz/pressrelease/3567
Advinus
Therapeutics Ltd, AlgiPharma AS, Allinky Biopharma, Alteogen Inc.,
Amakem NV, Ampio Pharmaceuticals, Inc., Angion Biomedica Corp.,
Apellis Pharmaceuticals Inc, Aridis Pharmaceuticals LLC, Achillion
Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca Plc, Asubio
Pharma Co., Ltd., Axikin Pharmaceuticals, Inc., Bayer AG, Beech Tree
Labs, Inc., Bioneer Corporation, Adamis Pharmaceuticals Corporation,
and Biotie Therapies Corp. are some of the key players in the COPD
therapeutics market in Asia Pacific.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment